Get the Stockscreener App
23.14
0.39%
0.09
Pre-market:
22.36
-0.78
-3.37%
10 X Genomics Inc stock is traded at $23.14, with a volume of 3.05M.
It is up +0.39% in the last 24 hours and up +15.99% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$23.05
Open:
$22.43
24h Volume:
3.05M
Relative Volume:
1.20
Market Cap:
$2.96B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-11.46
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
+22.50%
1M Performance:
+15.99%
6M Performance:
+73.07%
1Y Performance:
+116.46%
1-Day Range:
$21.83
$23.26
1-Week Range:
$18.52
$23.26
52-Week Range:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
23.14 | 2.94B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
181.45 | 29.92B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
53.31 | 9.52B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
41.58 | 7.47B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
77.93 | 6.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.25 | 4.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Is 10x Genomics Inc. still a buy after recent gains2025 Biggest Moves & AI Forecast Swing Trade Picks - mfd.ru
Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | 10x Genomics(TXG.US) Q4 2025 Earnings Conference - 富途牛牛
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com UK
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India
10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat
10x Genomics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey
10x Genomics Q4 Earnings Call Highlights - MarketBeat
10x Genomics, Inc. SEC 10-K Report - TradingView
10x Genomics: Fourth Quarter Financial Overview - Bitget
10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus
Can 10x Genomics Inc. stock outperform in a bear market2025 Top Decliners & High Return Trade Opportunity Guides - mfd.ru
10x Genomics (TXG) Q4 2025 Earnings Transcript - AOL.com
10x Genomics (TXG) Surpasses Q4 Revenue Expectations - GuruFocus
Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast By Investing.com - Investing.com India
Earnings call transcript: 10x Genomics beats Q4 2025 EPS forecast - Investing.com
10x Genomics (NASDAQ:TXG) Delivers Impressive Q4 CY2025 - Finviz
10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
10x Genomics Q4 2025 Financial Results: Loss Narrows, Revenue at $166MNews and Statistics - IndexBox
10x Genomics Q4 Loss Narrows, Revenue Rises; 2026 Guidance Set - marketscreener.com
10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
10x Genomics: Q4 Earnings Snapshot - kare11.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q4 Revenue $166.0M, vs. FactSet Est of $159.7M - marketscreener.com
10x Genomics Earnings Report: Q4 Overview - Benzinga
10x Genomics (NASDAQ: TXG) narrows 2025 losses and guides to modest 2026 growth - Stock Titan
10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 - PR Newswire
10X Genomics faces earnings test as new pricing strategy debuts By Investing.com - Investing.com South Africa
10X Genomics faces earnings test as new pricing strategy debuts - Investing.com
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Finansavisen
What makes 10x Genomics Inc. stock attractive todayQuarterly Profit Report & Free Community Consensus Stock Picks - mfd.ru
10x Genomics Earnings Preview - Sahm
10x Genomics Earnings Preview: Revenue Forecast, Analyst Estimates & Stock OutlookNews and Statistics - IndexBox
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - Finviz
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 190,059 Shares of 10x Genomics $TXG - MarketBeat
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):